Abstract

E-mail Abstract Author Add To Itinerary Session Search Abstracts Program

Session 50 Poster Session Therapeutic Vaccine Studies Session Time: 4:30-6:30 pm Room 4E-F

314-W. Therapeutic Immunization with Remune Alters Kinetics of Viral Rebound after Analytical Therapy Interruption (ATI) R. P. Bucy*1, R. B. Moss2, and M. Gersten3 for the 06A Study Team 1Univ. of Alabama, Birmingham; 2Immune Response Corp., Carlsbad, CA; and 3Agouron Pharmaceuticals, La Jolla, CA Background: The benefit of therapeutic immunization may be most clearly determined by analyzing the kinetics of viral rebound when patients stop all antiretroviral medications. Methods: Subjects from a randomized adjuvant-controlled Remune vaccine trial designed to detect clinical endpoints, who had maintained plasma HIV RNA <50 copies/mL for 6 months prior to entry, underwent a planned 6-week analytical therapy interruption (ATI). The double blind structure of the parent study was maintained and 20 Remune and 8 IFA subjects were enrolled. Plasma vRNA was measured at multiple time points during the ATI and a series of indices were calculated based on these data. Lymphocyte proliferation assay (LPA) responses and the frequency of cells producing IL-2 or IFN-gamma after HIV antigen stimulation were measured. Results: The slope of the initial rise in plasma vRNA was significantly slower (0.16 vs 0.21 log10copies/day) in the Remune vs control group (p<0.05). The peak and post peak low viral loads off therapy were lower in the Remune group, but this difference was not statistically significant. Of patients who remained off HAART or who restarted HAART after the peak viral load had been attained, 5 of 15 in the Remune group vs 1 of 6 in the control group had a post peak low of <5000 copies/mL. Although the LPA response to p24 antigen did not correlate with indices of viral rebound, the frequency of cells that produce IFN-gamma when stimulated with either p24 (CD4 T-cell responses) or vaccinia virus constructs expressing several HIV proteins (CD8 T-cell responses) was significantly increased in the REMUNE group. Both IL-2 and IFN-gamma frequencies were higher in subjects with a post peak low <5000 copies/mL, and the correlation of these responses to the post peak low viral load was statistically significant for the CD4 T cells response, but not for CD8 T-cell responses. By flow cytometry, the frequency of blood CD4 T cells fell while CD8 T cells rose during the ATI; both returned to baseline values when therapy was re-started. Conclusions: Therapeutic immunization with Remune increases both CD4 and CD8 T-cell immunity to HIV antigens and alters the kinetics of viral rebound during ATI. The relationship between in vitro CD4 and CD8 T-cell responses to viral antigen and the in vivo pattern of viral rebound are correlated, but somewhat different than expected.

©2002 9th Conference on Retroviruses and Opportunistic Infections